Literature DB >> 18322399

Human recombinant butyrylcholinesterase purified from the milk of transgenic goats interacts with beta-amyloid fibrils and suppresses their formation in vitro.

E Podoly1, T Bruck, S Diamant, N Melamed-Book, A Weiss, Y Huang, O Livnah, S Langermann, H Wilgus, H Soreq.   

Abstract

BACKGROUND: In Alzheimer's disease (AD), brain butyrylcholinesterase (BChE) co-localizes with beta-amyloid (Abeta) fibrils. AIMS: In vitro testing of the significance of this phenomenon to AD progress.
METHODS: A thioflavine T (ThT) fluorogenic assay, photo-induced cross-linking and quantifiable electron microscopy served to compare the effect on Abeta fibril formation induced by highly purified recombinant human BChE (rBChE) produced in the milk of transgenic goats with that of serum-derived human BChE.
RESULTS: Both proteins at 1:50 and 1:25 ratios to Abeta dose-dependently prolonged the ThT lag time and reduced the apparent rate of Abeta fibril formation compared to Abeta alone. Photo-induced cross-linking tests showed that rBChE prolonged the persistence of amyloid dimers, trimers and tetramers in solution, whereas Abeta alone facilitated precipitation of such multimers from solution. Transmission electron microscopy showed that rBChE at 1:100 to Abeta prevented the formation of larger, over 150-nm-long, Abeta fibrils and reduced fibril branching compared to Abeta alone as quantified by macro programming of Image Pro Plus software.
CONCLUSION: Our findings demonstrate that rBChE interacts with Abeta fibrils and can attenuate their formation, extension and branching, suggesting further tests of rBChE, with unlimited supply and no associated health risks, as a therapeutic agent for delaying the formation of amyloid toxic oligomers in AD patients. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322399     DOI: 10.1159/000113711

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  8 in total

Review 1.  Pharmacokinetic strategies for treatment of drug overdose and addiction.

Authors:  David A Gorelick
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

2.  Chemical polysialylation of human recombinant butyrylcholinesterase delivers a long-acting bioscavenger for nerve agents in vivo.

Authors:  Denis G Ilyushin; Ivan V Smirnov; Alexey A Belogurov; Igor A Dyachenko; Tatiana Iu Zharmukhamedova; Tatjana I Novozhilova; Eugene A Bychikhin; Marina V Serebryakova; Oleg N Kharybin; Arkadii N Murashev; Konstantin A Anikienko; Eugene N Nikolaev; Natalia A Ponomarenko; Dmitry D Genkin; G Michael Blackburn; Patrick Masson; Alexander G Gabibov
Journal:  Proc Natl Acad Sci U S A       Date:  2013-01-07       Impact factor: 11.205

3.  BuChE K variant is decreased in Alzheimer's disease not in fronto-temporal dementia.

Authors:  Alessandra Bizzarro; V Guglielmi; R Lomastro; A Valenza; A Lauria; C Marra; M C Silveri; F D Tiziano; C Brahe; C Masullo
Journal:  J Neural Transm (Vienna)       Date:  2010-03       Impact factor: 3.575

4.  It all starts at the ends: multifaceted involvement of C- and N-terminally modified cholinesterases in Alzheimer's disease.

Authors:  Amit Berson; Hermona Soreq
Journal:  Rambam Maimonides Med J       Date:  2010-10-31

5.  Reduced serum butyrylcholinesterase activity indicates severe systemic inflammation in critically ill patients.

Authors:  Aleksandar R Zivkovic; Karsten Schmidt; Annette Sigl; Sebastian O Decker; Thorsten Brenner; Stefan Hofer
Journal:  Mediators Inflamm       Date:  2015-02-11       Impact factor: 4.711

6.  Homomeric and Heteromeric Aβ Species Exist in Human Brain and CSF Regardless of Alzheimer's Disease Status and Risk Genotype.

Authors:  Erica Lana; Anna Gellerbring; Sabrina Jung; Agneta Nordberg; Christina Unger Lithner; Taher Darreh-Shori
Journal:  Front Mol Neurosci       Date:  2019-07-31       Impact factor: 5.639

7.  The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology.

Authors:  Erez Podoly; Deborah E Shalev; Shani Shenhar-Tsarfaty; Estelle R Bennett; Einor Ben Assayag; Harvey Wilgus; Oded Livnah; Hermona Soreq
Journal:  J Biol Chem       Date:  2009-04-21       Impact factor: 5.157

8.  Amyloid-β peptides act as allosteric modulators of cholinergic signalling through formation of soluble BAβACs.

Authors:  Rajnish Kumar; Agneta Nordberg; Taher Darreh-Shori
Journal:  Brain       Date:  2015-11-02       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.